Avidity Biosciences, Inc

Avidity Biosciences — Technical Presentation (December 2022)

65 slides from Avidity Biosciences's technical presentation, Dec 14, 2022

  1. Slide 1: AOC 1001 MARINA Phase 1/2 Trial Preliminary Data Assessment

    Virtual Investor & Analyst Event Series – Volume 6: AOC 1001 MARINATM Phase 1/2 Trial Preliminary Data Assessment Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including, but not limited to, statements regarding o

  3. Slide 3: Our Vision

    Our Vision To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Luke Living with DM1

  4. Slide 4: Delivering on Our Vision

    Delivering on Our Vision Progressing robust pipeline in muscle; 3 programs in clinical development in approx. a year AOC 1001* Phase 1/2 MARINATM trial and MARINA-OLETM ongoing AOC 1020 for FSHD in Phase 1/2 FORTITUDETM trial AOC 1044 for DMD in Phase 1/2 EXPLORE44TM trial Leveraging expertise in cl

  5. Slide 5: Delivering on 2022 Goals

    Delivering on 2022 Goals Three programs in three distinct rare diseases in clinical development DM1: AOC 1001* MARINATM Successfully completed preliminary assessment Top-line data and program updates planned for 2023 FSHD: AOC 1020 FORTITUDETM DMD: AOC 1044 EXPLORE44TM IND cleared; trial initiation

  6. Slide 6: Goals for the Day

    Goals for the Day AOC 1001 Preliminary Data Assessment Living with DM1 Disruptive and Broad AOC Platform Answer your questions mAb OLIGO AOC 1001

  7. Slide 7: Delivery to Muscle: AOCs Deliver to Muscle

    Delivery to Muscle AOCs Deliver to Muscle – Revolutionary Advancement for the Field of RNA Therapeutics MARINA Primary Endpoint; Phase 1/2 trial ongoing First-ever successful targeted delivery of RNA to muscle – reinforces disruptive and broad potential of the AOC platform DMPK Reduction 100% of tre

  8. Slide 8: Avidity Management Team Members

    Steve Hughes, M.D. Chief Medical Officer Sarah Boyce President and CEO Art Levin, Ph.D. Chief Scientific Officer Mike Flanagan, Ph.D. Chief Technical Officer AOC 1001 MARINATM Phase 1/2 Trial Preliminary Data Assessment Avidity Management Team Members Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia

  9. Slide 9: Agenda

    Agenda Sarah Boyce, President & CEO Steve Hughes, M.D., CMO Mike Flanagan, Ph.D., CTO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Art Levin, Ph.D., CSO Avidity Management Dr. Nicholas Johnson, VCU Kath Gallagher, SVP, Communications & IR (Moderator) Sarah Boyce, Presiden

  10. Slide 10: MARINA: A Phase 1/2 Clinical Trial of AOC 1001 in DM1

    Steve Hughes, M.D., Chief Medical Officer MARINA: A Phase 1/2 Clinical Trial to Evaluate AOC 1001 in Adult Patients with DM1

  11. Slide 11: Myotonic Dystrophy Type 1: Disease Overview

    0 APPROVED THERAPIES Myotonic Dystrophy Type 1 (DM1): Disease Overview >40,000 PEOPLE WITH DM1 IN THE US DM1 is a complex disease with symptoms that present with high variability from patient to patient Monogenic, autosomal dominant, progressive disease that primarily affects muscle: skeletal, cardi

  12. Slide 12: DM1 Caused by Toxic Gain-of-Function mRNA; Suited to siRNA

    DM1 is Caused by a Toxic Gain-of-Function mRNA and is Well Suited to an siRNA Approach Mutant DMPK mRNA Splicing Errors in Target mRNAs Potential Therapeutic Approach Reduces mRNA Splicing Errors AOC 1001 Oligonucleotide binds DMPK mRNA Mechanism of Disease MBNL Release Reduce Nuclear Foci Knock Dow

  13. Slide 13: AOC 1001's Preclinical Package

    IND AOC 1001’s Compelling Preclinical Package Safety and Tolerability Delivery to Muscle Impact on Disease Mechanism Favorable toxicology profile in Non-Human Primates (NHPs) Duration and delivery shown in wide range of muscles in multiple preclinical models DMPK Reduction 75% reduction in NHPs Spli

  14. Slide 14: MARINA and MARINA-OLE Trial Design

    N = ~44 Ages 18-65 (3:1 randomization) Part A receives single IV dose Part B receives multi-ascending IV doses Quarterly doses - 1 booster after first 6 weeks 6-month treatment and observation duration MARINATM and MARINA-OLETM Allow for Both Short- and Long-term Data Collection to Support AOC 1001*

  15. Slide 15: MARINA and MARINA-OLE Trial Design

    N = ~44 Ages 18-65 (3:1 randomization) Part A receives single IV dose Part B receives multi-ascending IV doses Quarterly doses - 1 booster after first 6 weeks 6-month treatment and observation duration MARINATM and MARINA-OLETM Allow for Both Short- and Long-term Data Collection to Support AOC 1001*

  16. Slide 16: Early Data from MARINA

    Early Data from MARINA Mid-Point at 6 weeks post 1 or 2 doses of AOC 1001 3:1 Randomization (AOC 1001:Placebo) Dose Booster Dose listed is siRNA Biopsy A 1 mg/kg Day 43 Day 92 BL B1 2 mg/kg Day 92 Day 183 BL Biopsy 1 mg/kg (n=8 Participants) 2mg/kg (n=12 Participants) Baseline Day 43 Baseline Day 92

  17. Slide 17: MARINA Partial Clinical Hold Update

    MARINATM is on a partial clinical hold for new participant enrollment The partial hold is in response to a serious adverse event (SAE) reported in a single participant in the 4mg/kg cohort. No similar events observed in other participants in either MARINA or the MARINA-OLE Avidity working to conclud

  18. Slide 18: Baseline Demographics Generally Well Matched Between Cohorts

    Baseline Demographics* Generally Well Matched Between Cohorts Mean (Range) or Number of subjects Cohort A1 (1 mg/kg) N=8 Cohort B1 (2 mg/kg) N=12 Age 37.9 (21–64) 38.8 (18-60) Sex Male: 2 / Female: 6 Male: 1 / Female: 11 BMI 22.0 (16.1–29.2) 25.0 (17.5–32.0) Mean CTG repeat length (range) 504 (150-7

  19. Slide 19: Generally Favorable Safety and Tolerability

    Generally Favorable Safety and Tolerability Subjects with ≥ 1 AE n (%) Placebo n=10 1mg/kg n=6 2mg/kg n=9 4mg/kg n=13 Total AOC 1001 N=28 Any AE 8 (80%) 6 (100%) 9 (100%) 12 (92%) 27 (96%) Related to study drug 2 (20%) 1 (17%) 3 (33%) 10 (77%) 14 (50%) Serious AE (SAE) 0 0 1 (11%) 1 (8%) 2 (7%) AE l

  20. Slide 20: Generally Favorable Safety and Tolerability

    Generally Favorable Safety and Tolerability Subjects with ≥ 1 AE n (%) Placebo n=10 1mg/kg n=6 2mg/kg n=9 4mg/kg n=13 Total AOC 1001 N=28 Any AE 8 (80%) 6 (100%) 9 (100%) 12 (92%) 27 (96%) Related to study drug 2 (20%) 1 (17%) 3 (33%) 10 (77%) 14 (50%) Serious AE (SAE) 0 0 1 (11%) 1 (8%) 2 (7%) AE l

  21. Slide 21: Summary

    Summary DM1 underrecognized, progressive and often fatal neuromuscular disease with a high unmet need and no approved therapies Data presented today is an early mid-point look at MARINA 6 weeks post 1 or 2 doses of AOC 1001 Baseline demographics generally well matched between cohorts Generally favor

  22. Slide 22: Delivering on the AOC Platform and Impacting DM1 Disease Mechanism

    Delivering on the AOC Platform and Impacting the Underlying Disease Mechanism of DM1 W. Michael Flanagan, Ph.D., Chief Technical Officer

  23. Slide 23: The DM1 Cascade to Functional Benefit

    The DM1 Cascade to Functional Benefit Early responders demonstrated myotonia improvement 16% splicing improvement across 22 gene panel 31% improvement in key muscle-specific panel 100% of treated participants had a DMPK Reduction 45% mean DMPK Reduction in treated participants Delivered RNA to muscl

  24. Slide 24: AOC 1001 Delivered siRNA to Muscle

    AOC 1001 Delivered siRNA to Muscle Potential to Expand siRNA Therapeutics Beyond Liver DELIVERY TO MUSCLE SPLICING IMPROVEMENT DMPK REDUCTION Dose Proportional Increase in Muscle siRNA Concentrations Single dose q6W x 2 q6W x 2 Day 43 after dose siRNA in Muscle (nM) n=6 n=9 n=3 FUNCTIONAL BENEFIT 1

  25. Slide 25: Every Treated Participant Showed DMPK Reduction

    Every Participant Treated with AOC1001 Showed DMPK Reduction* All Treated Participants Demonstrate DMPK Reduction DELIVERY TO MUSCLE SPLICING IMPROVEMENT DMPK REDUCTION FUNCTIONAL BENEFIT Placebo group combined from both cohorts and shown as standard error of mean Data represented as 6 weeks post la

  26. Slide 26: Meaningful DMPK RNA Reduction Observed in Muscle

    Meaningful DMPK RNA Reduction Observed in Muscle 45% DMPK reduction after a single dose at 1 mg/kg or two doses at 2mg/kg Mean % DMPK Reduction Data represented as 6 weeks post last dose DMPK % change from baseline - 46 % DELIVERY TO MUSCLE SPLICING IMPROVEMENT DMPK REDUCTION FUNCTIONAL BENEFIT 1mg/

  27. Slide 27: Why Is DMPK Inhibition Similar Between 1 and 2 mg/kg Doses?

    Why is DMPK inhibition similar between 1 and 2 mg/kg doses? Dose and Time Dependence: Potential to observe dose-dependent DMPK inhibition with higher and longer dosing siRNA Concentrations 3.3% Reduces mRNA Splicing Errors AOC 1001 Oligonucleotide binds DMPK mRNA MBNL Release Reduce Nuclear Foci Kno

  28. Slide 28: Sustained DMPK Reduction Leads to Dose-Dependent Splicing Improvements

    Sustained DMPK Reduction Leads to Dose-Dependent Splicing Improvements Splicing improvement 22-Gene Splicing Panel Splicing measured by targeted RNA sequencing and calculated using published formula (Tanner et. al 2021) % mean change is calculated as mean change from baseline/mean baseline score acr

  29. Slide 29: Splicing Improvements Demonstrate Impact on Disease Mechanism

    Splicing Improvements in Participants with DM1 Demonstrates AOC 1001 is Impacting Disease Mechanism Splicing improvement DELIVERY TO MUSCLE SPLICING IMPROVEMENT DMPK REDUCTION FUNCTIONAL BENEFIT Splicing measured by targeted RNA sequencing and calculated using published formula (Tanner et. al 2021)

  30. Slide 30: Muscle-Specific Biomarkers Show 31% Splicing Improvement

    Splicing improvement Splicing measured by targeted RNA sequencing and calculated using published formula (Tanner et. al 2021) Splicing Index for each participant is calculated as absolute change from baseline (4-gene panel) Data represented as 6 weeks post last dose with placebo group combined from

  31. Slide 31: Framework for Assessing Splicing Data

    Framework for Assessing Splicing Data Across 22 Genes in Healthy and DM1 Participants People with DM1 versus Healthy People Healthy People (N=25) Improvement Range of Splicing Events in Healthy People Percent Spliced In/Out Data from Charles Thornton, MD, University of Rochester Medical Center 22 Ge

  32. Slide 32: Framework for Assessing Splicing Data

    Framework for Assessing Splicing Data Across 22 Genes in Healthy and DM1 Participants People with DM1 versus Healthy People People with DM1 (N=172) Healthy People (N=25) Range of Splicing Events in People with DM1 Range of Splicing Events in Healthy People Improvement Percent Spliced In/Out 22 Gene

  33. Slide 33: Framework for Assessing Splicing Data

    Framework for Assessing Splicing Data Across 22 Genes in Healthy and DM1 Participants People with DM1 versus Healthy People People with DM1 (N=172) Healthy People (N=25) Range of Splicing Events in People with DM1 Range of Splicing Events in Healthy People Individual Participant Baseline Splicing Im

  34. Slide 34: Framework for Assessing Splicing Data

    Framework for Assessing Splicing Data Across 22 Genes in Healthy and DM1 Participants People with DM1 versus Healthy People People with DM1 (N=172) Healthy People (N=25) Range of Splicing Events in People with DM1 Range of Splicing Events in Healthy People Individual Participant Splicing Improvement

  35. Slide 35: Improved Splicing Across 22-gene Panel in Two Early Responders

    People with DM1 (N=172) Healthy People (N=25) Splicing change – study participant Population data from Charles Thornton, MD, University of Rochester Medical Center Early Responder 1 mg/kg, single dose Improvement Improvement Percent Spliced In/Out Percent Spliced In/Out Representative Placebo Partic

  36. Slide 36: AOC 1001 Shows Early Signs of Myotonia Benefit (1mg/kg)

    AOC 1001 Shows Early Signs of Myotonia Benefit Early responder from Cohort A (1mg/kg) shows improvement weeks after first dose ` Participant from 1mg/kg Single Dose Baseline vHOT Day 43 vHOT 6 weeks after single dose Day 92 vHOT 12 weeks after single dose Day 183 vHOT 24 weeks after single dose vHOT

  37. Slide 37: AOC 1001 Shows Early Signs of Myotonia Benefit (2mg/kg)

    AOC 1001 Shows Early Signs of Myotonia Benefit Early responder from Cohort B1 (2mg/kg) shows improvement weeks after first dose Day 43 vHOT 6 weeks after first dose Day 92 vHOT 6 weeks after second dose Participant from 2mg/kg Multidose Baseline vHOT Day 183 vHOT 12 weeks after third dose vHOT = vid

  38. Slide 38: AOC 1001 Shows Early Signs of Myotonia Benefit (2mg/kg)

    AOC 1001 Shows Early Signs of Myotonia Benefit Early responder from Cohort B1 (2mg/kg) shows improvement Participant from 2mg/kg Multidose Baseline vHOT Day 183 vHOT 12 weeks after third dose vHOT = video hand opening time Improvement visible at Day 43 that is sustained for at least 12 weeks followi

  39. Slide 39: Delivering on the Platform and Impacting Disease Mechanism

    Delivering on the Platform and Impacting Disease Mechanism Platform Achievements: AOC technology delivered siRNA to muscle – a first for the RNA field AOC 1001 achieved a meaningful DMPK reduction in 100% of treated participants 45% mean DMPK Reduction in treated participants DM1 Advancements: AOC 1

  40. Slide 40: Agenda

    Agenda Sarah Boyce, President & CEO Steve Hughes, M.D., CMO Mike Flanagan, Ph.D., CTO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Art Levin, Ph.D., CSO Avidity Management Dr. Nicholas Johnson, VCU Kath Gallagher, SVP, Communications & IR (Moderator) Sarah Boyce, Presiden

  41. Slide 41: Clinical Impact of Myotonic Dystrophy Type 1

    Clinical Impact of Myotonic Dystrophy Type 1 Nicholas E. Johnson, M.D., M.Sci., FAAN Vice Chair for Research, Department of Neurology, Virginia Commonwealth University Dr. Johnson is an associate professor, division chief of neuromuscular, and vice chair of research in the department of neurology at

  42. Slide 42: Clinical Impact of Myotonic Dystrophy Type 1

    Clinical Impact of Myotonic Dystrophy Type 1 Nicholas Johnson, MD, Msci, FAAN Vice Chair of Research, Associate Professor Director, Muscular Dystrophy Translational Program Departments of Neurology, Human Molecular Genetics Virginia Commonwealth University

  43. Slide 43: Myotonic Dystrophy Type 1

    Myotonic Dystrophy Type 1 Autosomal Dominant Core features in skeletal muscle Weakness/wasting Preferentially affects distal, cranial, and respiratory muscles Myotonia Preferentially affects hand/forearm muscles Multi-systemic Mean age of death is age 55 Example of grip myotonia

  44. Slide 44: Other Systems

    Other Systems Respiratory Respiratory failure is most common cause of death Cardiac Bradycardia, heart block, sudden death Ocular Cataracts Gastrointestinal Smooth muscle is affected Endocrine insulin resistance CNS Sleep regulation A range of behavioral & cognitive changes may occur Increased risk

  45. Slide 45: Myotonia Is a Prevalent Cause of Disability

    Myotonia is a prevalent cause of disability Survey of 1,180 Individuals with myotonic dystrophy (457 DM1 participants) Hagerman, et al. 2019

  46. Slide 46: Myotonia in DM1 Relates to Ion Channelopathies

    Myotonia score ASO control Twice weekly SQ injection transgenic mice Myotonia in DM1 relates to ion channelopathies Chloride channel mis-splicing causes myotonia Calcium channel mis-splicing aggravates myotonia Together they may also cause inexcitability / weakness Hands are selectively affected Age

  47. Slide 47: Correction of Chloride Channel Splicing Improves Myotonia

    Correction of chloride channel splicing improves myotonia Wheeler, et al., 2007 Mouse model of myotonic dystrophy (HSA LR ) Use ASO to correct chloride channel splicing associated with DM1 Correction of chloride channel improves myotonia

  48. Slide 48: The Importance of Myotonia

    The Importance of Myotonia Prevalent cause of disability Directly tied to repeat expansion Channel dysfunction (e.g., myotonia) may change faster than strength

  49. Slide 49: Natural History Study for the DMCRN

    Current natural history study for the Myotonic Dystrophy Clinical Research Network (DMCRN) Enrolling 700 participants Observation period: 24 months Characterizing endpoints, patient-reported outcomes, and patient populations to support design and recruitment of interventional trials END-DM1, Establi

  50. Slide 50: Specific Goals of END-DM1 Study

    Specific goals of END-DM1 study Characterize DM1 severity and disease progression over two years in a large cohort (n = 700) Determine basal levels of impairment using standardized measures motor function and muscle strength and a patient-reported outcome (PRO) Test for patient characteristics at ba

  51. Slide 51: END-DM1 International Network

    700 patients (320 enrolled) International network Supported by FDA. Now also buttressed by Myotonic Dystrophy Foundation and industry* (expansion to EU/NZ/CA) * Avidity Biosciences, Dyne Therapeutics, Entrada Therapeutics, Vertex Pharmaceuticals Scheme of END-DM1 study baseline 1 yr 2 yr study visit

  52. Slide 52: Clinical Outcomes in END-DM1 Study

    Clinical outcomes in END-DM1 study Mobility (leg function) 10 m walk/run 6-minute walk Timed up and go 4 stair climb Respiratory function vital capacity sitting and supine Hand function 9-hole peg Grip strength Pinch strength Myotonia Video-recorded hand opening time (vHOT) General muscle function Q

  53. Slide 53: Summary

    Summary DM1 is a prevalent disease with significant morbidity and mortality The DMCRN natural history studies inform therapeutic trial design including: COAs Biomarkers This support will be provided to the Avidity program

  54. Slide 54: Agenda

    Agenda Sarah Boyce, President & CEO Steve Hughes, M.D., CMO Mike Flanagan, Ph.D., CTO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Art Levin, Ph.D., CSO Avidity Management Dr. Nicholas Johnson, VCU Kath Gallagher, SVP, Communications & IR (Moderator) Sarah Boyce, Presiden

  55. Slide 55: Delivering on the RNA Revolution

    Delivering on the RNA Revolution Art Levin, Ph.D., Chief Scientific Officer

  56. Slide 56: The DM1 Cascade to Functional Benefit

    DELIVERY TO MUSCLE DMPK REDUCTION SPLICING IMPROVEMENT The DM1 Cascade to Functional Benefit EARLY SIGNS OF CLINICAL ACTIVITY Splicing improvements leading to early signs of clinical activity with improvement in myotonia

  57. Slide 57: Avidity Followed the Data to Engineer AOCs

    Avidity Followed the Data to Engineer AOCs - A Powerful Potential New Class of Drugs Designed to combine the proven and safe technologies of approved monoclonal antibodies and oligonucleotides Specificity of targeting with mAbs Potency & precision of oligonucleotides Targets tissues with durable age

  58. Slide 58: AOCs Deliver to Muscle: A Breakthrough for RNA Therapeutics

    AOCs Deliver to Muscle Starting A Breakthrough for RNA Therapeutics ANTIBODY OLIGONUCLEOTIDE CONJUGATE (AOC) mAb OLIGO Past 30 Years 2021 First AOC Dosed in Humans Today AOCs deliver RNA to Skeletal Muscle CARDIAC IMMUNOLOGY OTHER INDICATIONS 2023 and Beyond RNA Therapies GalNAc Focused on the liver

  59. Slide 59: Delivering on the RNA Revolution

    Delivering on the RNA Revolution Broad and disruptive AOC platform - new class of RNA therapeutics Followed the data to design and engineer AOCs Delivered siRNA to muscle for the first time ever with AOC 1001 - a breakthrough for the field of RNA therapeutics AOC platform expands ability to address

  60. Slide 60: Delivering on the RNA Revolution

    Delivering on the RNA Revolution

  61. Slide 61: Agenda

    Agenda Sarah Boyce, President & CEO Steve Hughes, M.D., CMO Mike Flanagan, Ph.D., CTO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Art Levin, Ph.D., CSO Avidity Management Dr. Nicholas Johnson, VCU Kath Gallagher, SVP, Communications & IR (Moderator) Sarah Boyce, Presiden

  62. Slide 62: Agenda

    Agenda Sarah Boyce, President & CEO Steve Hughes, M.D., CMO Mike Flanagan, Ph.D., CTO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Art Levin, Ph.D., CSO Avidity Management Dr. Nicholas Johnson, VCU Kath Gallagher, SVP, Communications & IR (Moderator) Sarah Boyce, Presiden

  63. Slide 63: Delivery to Muscle: AOCs Deliver to Muscle

    Delivery to Muscle AOCs Deliver to Muscle – Revolutionary Advancement for the Field of RNA Therapeutics MARINA Primary Endpoint; Phase 1/2 trial ongoing First-ever successful targeted delivery of RNA to muscle – reinforces disruptive and broad potential of the AOC platform DMPK Reduction 100% of tre

  64. Slide 64: Delivering on the RNA Revolution: Delivering Next

    Delivering on the RNA Revolution Pursuing preclinical proof of concept in additional skeletal muscle and other tissues DELIVERING NEXT

  65. Slide 65: AOC 1001 MARINA Phase 1/2 Trial Preliminary Data Assessment

    Virtual Investor & Analyst Event Series – Volume 6: AOC 1001 MARINATM Phase 1/2 Trial Preliminary Data Assessment

Avidity Biosciences — Technical Presentation (December 2022) on 6ix